Literature DB >> 23450810

Automatic cell cloning assay for determining the clonogenic capacity of cancer and cancer stem-like cells.

Radek Fedr1, Zuzana Pernicová, Eva Slabáková, Nicol Straková, Jan Bouchal, Michal Grepl, Alois Kozubík, Karel Souček.   

Abstract

The clonogenic assay is a well-established in vitro method for testing the survival and proliferative capability of cells. It can be used to determine the cytotoxic effects of various treatments including chemotherapeutics and ionizing radiation. However, this approach can also characterize cells with different phenotypes and biological properties, such as stem cells or cancer stem cells. In this study, we implemented a faster and more precise method for assessing the cloning efficiency of cancer stem-like cells that were characterized and separated using a high-speed cell sorter. Cell plating onto a microplate using an automatic cell deposition unit was performed in a single-cell or dilution rank mode by the fluorescence-activated cell sorting method. We tested the new automatic cell-cloning assay (ACCA) on selected cancer cell lines and compared it with the manual approach. The obtained results were also compared with the results of the limiting dilution assay for different cell lines. We applied the ACCA to analyze the cloning capacity of different subpopulations of prostate and colon cancer cells based on the expression of the characteristic markers of stem (CD44 and CD133) and cancer stem cells (TROP-2, CD49f, and CD44). Our results revealed that the novel ACCA is a straightforward approach for determining the clonogenic capacity of cancer stem-like cells identified in both cell lines and patient samples.
Copyright © 2013 International Society for Advancement of Cytometry.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23450810     DOI: 10.1002/cyto.a.22273

Source DB:  PubMed          Journal:  Cytometry A        ISSN: 1552-4922            Impact factor:   4.355


  11 in total

1.  Lentiviral vector-mediated insertional mutagenesis screen identifies genes that influence androgen independent prostate cancer progression and predict clinical outcome.

Authors:  Arun K Nalla; Theodore F Williams; Casey P Collins; Dustin T Rae; Grant D Trobridge
Journal:  Mol Carcinog       Date:  2015-10-29       Impact factor: 4.784

2.  ATR inhibition sensitizes liposarcoma to doxorubicin by increasing DNA damage.

Authors:  Juncheng Cui; Dylan Dean; Francis J Hornicek; Raphael E Pollock; Robert M Hoffman; Zhenfeng Duan
Journal:  Am J Cancer Res       Date:  2022-04-15       Impact factor: 5.942

3.  Inhibition of NANOG/NANOGP8 downregulates MCL-1 in colorectal cancer cells and enhances the therapeutic efficacy of BH3 mimetics.

Authors:  Abid R Mattoo; Jingyu Zhang; Luis A Espinoza; J Milburn Jessup
Journal:  Clin Cancer Res       Date:  2014-09-10       Impact factor: 12.531

4.  Cisplatin or LA-12 enhance killing effects of TRAIL in prostate cancer cells through Bid-dependent stimulation of mitochondrial apoptotic pathway but not caspase-10.

Authors:  Olga Vondálová Blanářová; Barbora Šafaříková; Jarmila Herůdková; Martin Krkoška; Silvie Tománková; Zuzana Kahounová; Ladislav Anděra; Jan Bouchal; Gvantsa Kharaishvili; Milan Král; Petr Sova; Alois Kozubík; Alena Hyršlová Vaculová
Journal:  PLoS One       Date:  2017-11-28       Impact factor: 3.240

5.  WAPL maintains a cohesin loading cycle to preserve cell-type-specific distal gene regulation.

Authors:  Ning Qing Liu; Michela Maresca; Teun van den Brand; Luca Braccioli; Marijne M G A Schijns; Hans Teunissen; Benoit G Bruneau; Elphѐge P Nora; Elzo de Wit
Journal:  Nat Genet       Date:  2020-12-14       Impact factor: 38.330

Review 6.  Current Stem Cell Biomarkers and Their Functional Mechanisms in Prostate Cancer.

Authors:  Kaile Zhang; Shukui Zhou; Leilei Wang; Jianlong Wang; Qingsong Zou; Weixin Zhao; Qiang Fu; Xiaolan Fang
Journal:  Int J Mol Sci       Date:  2016-07-19       Impact factor: 5.923

7.  Distinct Cell-Cycle Control in Two Different States of Mouse Pluripotency.

Authors:  Menno Ter Huurne; James Chappell; Stephen Dalton; Hendrik G Stunnenberg
Journal:  Cell Stem Cell       Date:  2017-10-05       Impact factor: 24.633

8.  Cardiomyogenic Heterogeneity of Clonal Subpopulations of Human Bone Marrow Mesenchymal Stem Cells.

Authors:  Naresh Kumar Tripathy; Syed Husain Mustafa Rizvi; Saurabh Pratap Singh; Venkata Naga Srikanth Garikpati; Soniya Nityanand
Journal:  J Stem Cells Regen Med       Date:  2018-05-30

Review 9.  Cancer Stem Cells in Head and Neck Squamous Cell Carcinoma: Identification, Characterization and Clinical Implications.

Authors:  Claudia Peitzsch; Jacqueline Nathansen; Sebastian I Schniewind; Franziska Schwarz; Anna Dubrovska
Journal:  Cancers (Basel)       Date:  2019-05-02       Impact factor: 6.639

10.  T-LAK cell-originated protein kinase (TOPK): an emerging prognostic biomarker and therapeutic target in osteosarcoma.

Authors:  Pichaya Thanindratarn; Ran Wei; Dylan C Dean; Arun Singh; Noah Federman; Scott D Nelson; Francis J Hornicek; Zhenfeng Duan
Journal:  Mol Oncol       Date:  2021-06-29       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.